Fumaric acid esters in the management of severe psoriasis

Clinical and Experimental Dermatology

Volumn 32, Issue 3, 2007, Pages 246-249

  Brewer, L ^a   Rogers, S ^a  

^a City of Dublin Skin/Cancer Hospital   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; EMOLLIENT AGENT; FUMADERM;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA; FATIGUE; FEMALE; FLUSHING; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT INFORMATION; PRIORITY JOURNAL; PSORIASIS; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; DERMATOLOGIC AGENTS; ESTERS; FEMALE; FUMARATES; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES;

EID: 33947625032     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2007.02389.x     Document Type: Article

References (14)

1. Schweckendiek W. Heiling von Psoriasis vulgaris. Med Montatsschr 1959; 13: 103-4.
2. Ockenfels HM, Schultewolter T, Ockenfels G et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139: 390-5.
3. Litjens NHR, Nibbering PH, Barrois AJ et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003; 148: 444-51.
4. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. Br J Dermatol 1999; 141: 424-9.
5. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992; 27: 769-71.
6. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multi-centre double blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-81.
7. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German multicentre study. Br J Dermatol 1998; 138: 456-60.
8. Nieboer C, de Hoop D, van Loenen AC et al. Systemic therapy with fumaric acid derivatives. New possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989; 20: 601-8.
9. Thio HB, van der Schroeff JG, Nugteren-Huying WM et al. Long-term systemic therapy with dimethylfumarate and monoethylfumarate in psoriasis. J Eur Acad Dermatol Venereol 1995; 4: 35-40.
10. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 2004; 150: 741-6.
11. Harries MJ, Chalmers RJG, Griffiths CEM. Fumaric acid esters for severe psoriasis; a review of 58 cases treated at one UK centre. Br J Dermatol 2004; 151 (Suppl.): 7.
12. Wain EM, Ronda L, Barker JNWN et al. Prospective, open, nonrandomized study investigating efficacy and safety of fumaric acid esters in a cohort of patients with severe recalcitrant, chronic plaque psoriasis. Br J Dermatol 2004; 151 (Suppl.): 6.
13. Hoefnagel JJ, Thio HB, Willemze R et al. Long term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363-9.
14. Lehmann M, Risch K, Nizze H et al. Fumaric acid esters are potent immunosuppressants. inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate. Arch Dermatol Res 2002; 294: 399-404.